Published: June 3, 2022 | Tags: BMS, Acquire, Turning Point Therapeutics, ~$4.1B
Ionis Partner Biogen Report Results of Tofersen in P-III (VALOR) study and OLE to Treat SOD1-ALS
Published: June 3, 2022 | Tags: Ionis, Biogen, Tofersen, P-III, VALOR Study, OLE, SOD1-ALS
InterVenn Biosciences Presents Results of DAWN IO Melanoma as a Novel Liquid Biopsy Test for the Treatment of Cancer at ASCO 2022
Published: June 3, 2022 | Tags: InterVenn Biosciences, DAWN IO Melanoma, Liquid Biopsy Test, Cancer
BMS Reports Results of Orencia (abatacept) in P-III (ACTIV-1) Trial for the Treatment of COVID-19
Published: June 3, 2022 | Tags: BMS, Orencia, abatacept, P-III, ACTIV-1 Trial, COVID-19
Regeneron Entered into Amended and Restated License Agreement with Sanofi for Libtayo (cemiplimab) to Treat Cancer
Published: June 3, 2022 | Tags: Regeneron, Sanofi, Libtayo, cemiplimab, Cancer, VelocImmune technology
Boehringer Ingelheim Entered into a License Agreement with A*STAR to Develop and Commercialize Targeted Cancer Therapies Using Innovative Antibodies
Published: June 3, 2022 | Tags: Boehringer Ingelheim, A*STAR, Antibodies, Cancer
BMS Collaborated with Immatics to Develop Allogeneic Cell Therapy Programs
Published: June 2, 2022 | Tags: BMS, Collaborated with Immatics to Develop Allogeneic Cell Therapy Programs
Takeda’s Revestive (teduglutide) Receives NICE Recommendation for the Treatment of Adults and Children with Short Bowel Syndrome
Published: June 2, 2022 | Tags: Takeda, Revestive, teduglutide, NICE, Recommendation, Short Bowel Syndrome
BMS Presents Results of Deucravacitinib in P-II (PAISLEY) Study for the Treatment of Systemic Lupus Erythematosus at EULAR 2022
Published: June 2, 2022 | Tags: BMS, Deucravacitinib, P-II, PAISLEY Study, Systemic Lupus Erythematosus, EULAR, 2022
Asher Bio Entered into a Clinical Trial Collaboration with Merck to Evaluate AB248 + Keytruda (pembrolizumab) for Locally Advanced or Metastatic Solid Tumors
Published: June 2, 2022 | Tags: Asher Bio, Merck, AB248, Keytruda, pembrolizumab, Solid Tumors
Axsome Publishes Results of AXS-05 (dextromethorphan-bupropion) in P-III (GEMINI) Trial for Major Depressive Disorder in The Journal of Clinical Psychiatry
Published: June 2, 2022 | Tags: Axsome, AXS-05, dextromethorphan-bupropion, P-III, GEMINI Trial, Major Depressive Disorder Journal of Clinical Psychiatry
Repare Entered into a Worldwide License and Collaboration Agreement with Roche to Develop and Commercialize Camonsertib (RP-3500) for Cancers
Published: June 2, 2022 | Tags: Repare, Roche, Camonsertib, RP-3500, Cancers
Janssen Reports Results of Tremfya (guselkumab) in P-III Studies Demonstrated Durable Efficacy Across Joint and Axial Symptoms for Active Psoriatic Arthritis
Published: June 1, 2022 | Tags: Janssen, Tremfya, guselkumab, P-III Studies, Active Psoriatic Arthritis
Astellas Entered into a Research Collaboration and License Agreement with GO Therapeutics to Develop Novel Immuno-Oncology Therapies
Published: June 1, 2022 | Tags: Astellas, GO Therapeutics, Novel, Immuno-Oncology, Therapies, ACCEL Technology
Timber Pharmaceuticals’ TMB-001 Receives the US FDA’s Breakthrough Therapy Designation for the Treatment of Congenital Ichthyosis
Published: June 1, 2022 | Tags: Timber Pharmaceuticals, TMB-001, US, FDA, Breakthrough Therapy Designation, Congenital Ichthyosis
Abbott’s FreeStyle Libre 3 System Receives the US FDA’s Clearance for the Treatment of Diabetes
Published: June 1, 2022 | Tags: Abbott, FreeStyle Libre 3 System, US, FDA, Clearance, Diabetes
Denali Therapeutics and Biogen Initiate P-IIb (LUMA) Study of BIIB122 for the Treatment of Parkinson’s Disease
Published: June 1, 2022 | Tags: Denali Therapeutics, Biogen, P-IIb, LUMA Study, BIIB122, Parkinson’s Disease
BioMarin to Presents Results of in P-I/II Study for the Treatment of Hemophilia A at ISTH 2022
Published: June 1, 2022 | Tags: BioMarin, Valoctocogene Roxaparvovec, P-I/II Study, Hemophilia A, ISTH 2022
Innodem Neurosciences’ ETNA Device Receives the US FDA’s Breakthrough Device Designation for the Treatment of Multiple Sclerosis
Published: May 31, 2022 | Tags: Innodem Neurosciences, ETNA Device, US, FDA, Breakthrough Device Designation, Multiple Sclerosis
Eledon Reports Results of Tegoprubart in P-IIa Trial Demonstrated Safety, Target Engagement, and Biomarker Response for ALS
Published: May 31, 2022 | Tags: Eledon, Tegoprubart, P-IIa Trial, Target Engagement, Biomarker Response, ALS
Regeneron & Sanofi Report the US FDA Acceptance of sBLA for Priority Review of Dupixent (dupilumab) to Treat Prurigo Nodularis
Published: May 31, 2022 | Tags: Regeneron, Sanofi, US, FDA, sBLA, Priority Review, Dupixent, dupilumab, Prurigo Nodularis
GSK to Acquire Affinivax for ~$3.3B
Published: May 31, 2022 | Tags: GSK, Acquire, Affinivax, ~$3.3B
Genentech’s Evrysdi (risdiplam) Receives the US FDA’s Approval for the Treatment of Spinal Muscular Atrophy in Babies Aged Under Two Months
Published: May 31, 2022 | Tags: Genentech, Evrysdi, risdiplam, US, FDA, Approval, Spinal Muscular Atrophy
Pharnext Reports the Completion of Patient Enrollment in the P-III (PREMIER) Trial of PXT3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A
Published: May 31, 2022 | Tags: Pharnext, P-III, PREMIER Trial, PXT3003, Charcot-Marie-Tooth Disease Type 1A
IASO Biotherapeutics Reports the NMPA’s Acceptance of IND Application for Equecabtagene Autoleucel to Treat Neuromyelitis Optica Spectrum Disorder
Published: May 30, 2022 | Tags: IASO Biotherapeutics, NMPA, IND, Equecabtagene Autoleucel, Neuromyelitis Optica Spectrum Disorder
AstraZeneca Reports the First Patients Dosing of Saphnelo (anifrolumab) in the P-III (IRIS) Trial for the Treatment of Lupus Nephritis
Published: May 30, 2022 | Tags: AstraZeneca, Saphnelo, anifrolumab-fnia, P-III, IRIS Trial, Lupus Nephritis
PharmEnable Entered into a Multi-Target Collaboration with Denali to Discover Therapies for the Treatment of Neurodegenerative Disease
Published: May 30, 2022 | Tags: PharmEnable, Denali, AI Drug Discovery Platform, Neurodegenerative Disease
Novartis’ Kymriah (tisagenlecleucel) CAR-T Cell Therapy Receives the US FDA’s Approval for the Treatment of Follicular Lymphoma
Published: May 30, 2022 | Tags: Novartis, Kymriah, tisagenlecleucel, CAR-T, Cell Therapy, US, FDA, Approval, Follicular Lymphoma
Inovio Presents Results of INO-5401 + INO-9012 & Libtayo (cemiplimab) for the Treatment of Glioblastoma at ASCO 2022
Published: May 30, 2022 | Tags: Inovio, INO-5401, INO-9012, Libtayo, cemiplimab, Glioblastoma, ASCO, 2022
BMS’ Opdivo (nivolumab) + Yervoy (ipilimumab) Receives the US FDA Approval as 1L Treatment for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Published: May 30, 2022 | Tags: BMS, Opdivo, nivolumab, Yervoy, ipilimumab, US, FDA, Approval, Esophageal Squamous Cell Carcinoma
Related Post: PharmaShots Weekly Snapshots (May 23 – 27, 2022)
